IPSC-derived astrocytes and methods for their use

JP2025525436A5Pending Publication Date: 2026-07-06FUJIFILM HOLDINGS AMERICA CORP +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
FUJIFILM HOLDINGS AMERICA CORP
Filing Date
2023-06-29
Publication Date
2026-07-06

AI Technical Summary

Technical Problem

Existing methods for differentiating induced pluripotent stem cells (iPSCs) into astrocytes are not efficient, compliant with Good Manufacturing Practice (GMP), and do not provide a xeno-free, feeder-free, and conditioned medium-free environment, which is crucial for clinical applications.

Method used

A method involving culturing neural progenitor cells (NPCs) derived from iPSCs in the presence of leukemia inhibitory factor (LIF) receptor ligands and lipid concentrates under defined conditions to generate astrocytes, using extracellular matrix proteins like laminin and vitronectin, and maintaining hypoxic or normoxic conditions to achieve high purity and functionality.

Benefits of technology

The method produces highly pure astrocytes expressing key markers such as CD44, NFIX, and GFAP, with glutamate uptake capability, suitable for clinical applications and capable of mimicking human brain development and neurodegeneration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000053_0000
    Figure 00000053_0000
  • Figure 00000053_0001
    Figure 00000053_0001
  • Figure 00000053_0002
    Figure 00000053_0002
Patent Text Reader

Abstract

The present disclosure provides methods for generating glial-biased neural progenitor cells from induced pluripotent cells and further differentiating the neural progenitor cells into astrocytes. Further provided herein are methods for using astrocytes in screening assays, models that mimic the human brain, and cell therapy.
Need to check novelty before this filing date? Find Prior Art